Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiation OncologyAetna proton/neutron/carbon radiotherapy Coverage …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0270

    Proton Beam, Neutron Beam, and Carbon Ion Radiotherapy

    Customize your policy alerts

    Sign up for Aetna Policy 0270 alerts

    Get alerted when Policy 0270 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy defines Aetna's medical necessity, experimental/investigational determinations, and coding guidance for proton beam, neutron beam, and carbon ion radiotherapy for members and providers.

    Policy Summary
    PayerAetna
    PolicyProton Beam, Neutron Beam, and Carbon Ion Radiotherapy
    Policy CodePolicy 0270
    Change TypeNo material change
    Effective DateJul 16, 1998
    Last ReviewOct 3, 2023
    Next Review DateMar 14, 2024
    Key ActionObtain prior authorization and document that medical necessity criteria are met (indication, prior radiation history, and inability of photon therapy to meet normal tissue constraints) before approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    16+Medically necessary indications
    ExperimentalCIRT status
    Salivary glandNeutron therapy supported
    LimitedComparative evidence
    10/03/2023Document review date

    Coverage Criteria and Evidence Summary

    Proton Beam Therapy - Medical Necessity

    Covered when ANY of the following tumor- or patient-specific conditions are met:

    PBRT covered indications: Primary CNS tumors; OR Head and neck tumors that are T4 or unresectable (excluding T1-T2N0M0 laryngeal cancer); OR Paranasal sinus, other accessory sinus, or nasopharyngeal tumors; OR Skull-based tumors (e.g., chordomas or chondrosarcomas); OR Malignancies in children (21 years of age and younger); OR Esophageal cancer; OR Malignancies requiring craniospinal irradiation in persons with no active extracranial disease; OR Mediastinal lymphomas; OR Thymomas and thymic carcinoma; OR Thoracic sarcomas; OR Nonmetastatic retroperitoneal sarcomas; OR Ocular tumors including intraocular/uveal melanoma (iris, ciliary body, choroid); OR Primary or metastatic tumors of the spine where spinal cord tolerance would be exceeded with photon approaches; OR Primary malignant or benign bone tumors; OR Reirradiation of an in-field or marginal recurrence being treated with curative intent when other radiotherapy approaches would exceed acceptable constraints; OR Localized unresectable hepatocellular carcinoma or intrahepatic cholangiocarcinoma in the curative setting when sparing of surrounding normal tissue cannot be achieved with standard techniques (including IMRT, SBRT, selective internal radiation spheres, transarterial therapy); OR Non-metastatic advanced unresectable pelvic tumors with significant bulky pelvic or periaortic nodes where other approaches would exceed constraints; OR Single kidney or transplanted pelvic kidney where maximal organ avoidance is critical; OR Persons with genetic syndromes requiring minimization of total radiation volume (e.g., NF-1, BRCA1/2, deleterious ATM mutations, Li-Fraumeni, Lynch syndrome, retinoblastoma).

    From Aetna policy list of medically necessary indications for proton beam radiotherapy (items 1–19).

    Policy Summary
    PayerAetna
    PolicyProton Beam, Neutron Beam, and Carbon Ion Radiotherapy
    Policy CodePolicy 0270
    Change TypeNo material change
    Effective DateJul 16, 1998
    Last ReviewOct 3, 2023
    Next Review DateMar 14, 2024
    Key ActionObtain prior authorization and document that medical necessity criteria are met (indication, prior radiation history, and inability of photon therapy to meet normal tissue constraints) before approval.
    SourceLink
    On This Page
    Coverage Criteria and Evidence SummaryBilling Codes and Diagnostic MappingPrior Authorization, Documentation, and Decision SupportBackground and ScopeDefinitions and Key TermsPolicy Dates and References

    Proton Beam Therapy - Prostate cancer stance

    Prostate cancer: For localized cancer of an intact prostate, proton beam radiotherapy (PBRT) and intensity-modulated radiation therapy (IMRT) are considered clinically equivalent; medical necessity will be determined by the member's benefit plan.

    Check member benefit plan definitions for coverage determination.

    Neutron Beam Therapy - Medical Necessity

    Covered when ANY of the following are present for salivary gland tumors:

    NBT covered indications: Inoperable salivary gland tumor; OR Locally advanced salivary gland tumor, especially with gross residual disease; OR Unresectable salivary gland tumor.

    Fast neutron radiotherapy indications for salivary gland malignancies per policy.

    Experimental and Investigational

    Not covered (experimental/investigational) when any of the following apply:

    PBRT experimental indications: All other indications not specified as medically necessary for PBRT in this policy (examples in adults include, but are not limited to: age-related macular degeneration; angiosarcoma; bladder cancer; breast cancer; cardiac intimal sarcoma; carotid body tumor; cavernous hemangioma; cervical cancer; extrahepatic cholangiocarcinoma; choroidal hemangioma; dermatofibrosarcoma protuberans; desmoid fibromatosis; Ewing's sarcoma; fibrosarcoma of extremities; hemangioblastoma; hemangioendothelioma; Hodgkin's lymphoma; intracranial AVMs; large cell lymphoma; leiomyosarcoma of extremities; liposarcoma; liver metastases; lung cancer including NSCLC; mesothelioma; multiple myeloma; non-Hodgkin lymphoma [except mediastinal lymphomas]; non-uveal melanoma; palliative treatment; pancreatic cancer; metastatic prostate cancer; rectal cancer; and others listed in policy).

    Policy lists these as experimental/investigational because effectiveness not established.

    CIRT stance: Carbon ion radiotherapy (CIRT) is considered experimental and investigational for all indications because its effectiveness has not been established.

    CIRT experimental status per policy.

    ASTRO Group 1 indications (summary)

    Professional-society based grouping of indications (ASTRO model policy summaries):

    Group 1 General: Group 1 (disease sites that frequently support PBT): pediatric tumors (≤21 years) treated with curative intent; adolescent/young adult (22–39) when criteria apply; patients with genetic syndromes requiring minimization of irradiated volume; medically inoperable patients where dose escalation is required; re-irradiation cases where cumulative critical-structure dose would exceed tolerance; primary malignant or benign bone tumors.

    ASTRO model policy (2023) Group 1 general indications.

    Group 1 Anatomical: Group 1 anatomical examples: CNS – ocular tumors, skull-base tumors (e.g., chordoma, chondrosarcoma), malignant and benign primary CNS tumors (excluding IDH wild-type GBM for curative intent), spine/spinal cord tumors and craniospinal irradiation; Head & Neck – nasopharynx, nasal cavity, paranasal sinuses, advanced/unresectable H&N cancers; Thoracic – esophageal cancer, mediastinal tumors including thymic tumors and mediastinal lymphomas, thoracic sarcomas; Abdominal – hepatocellular and intra-hepatic biliary cancers, non-metastatic retroperitoneal sarcomas; Pelvic – advanced/unresectable pelvic tumors with significant nodal disease and single/transplanted pelvic kidney cases.

    ASTRO model policy (2017, 2023) Group 1 specifics.

    ASTRO Group 2 indications (summary)

    ASTRO Group 2 (coverage with evidence development):

    Group 2 (suitable for Coverage with Evidence Development): non-T4/resectable head and neck cancers; thoracic malignancies including non-metastatic primary lung and esophageal cancers and mediastinal lymphomas; abdominal malignancies including pancreatic, biliary and adrenal cancers; pelvic malignancies including non-metastatic rectal, anal, bladder and cervical cancers; non-metastatic prostate cancer; and breast cancer.

    ASTRO model policy (2017) Group 2 indications for CED.

    HTA consensus and evidence limitations

    General evidence-based stance from multiple HTAs and assessments:

    Evidence quality and general conclusions: Comparative evidence is limited and generally low quality for most indications; randomized trials and high-quality comparative studies are lacking, limiting conclusions about superiority of particle therapy versus photon therapy.

    Summarizes findings from VHA, CADTH, AHRQ, VATAP, KCE and others.

    Indications with more consistent support: Ocular tumors, pediatric CNS tumors, and selected skull-base tumors (e.g., chordomas/chondrosarcomas) have more supportive data and are commonly accepted indications.

    Noted across multiple HTAs and assessments.

    Indications with insufficient or concerning evidence: Prostate cancer, some breast cancer contexts, certain intramedullary spinal cord gliomas, and many common adult cancers lack convincing evidence of superiority; some studies even suggest worse outcomes or adverse cosmetic results in select settings.

    Concerns reported by multiple assessments (KCE, VATAP, CADTH, etc.).

    Supported, Unsupported, and Trial/Registry Use

    Indications and contexts where particle therapy is discussed as appropriate or insufficiently supported:

    Indications with some support: Particle therapy (proton) may be indicated or considered for skull-base tumors (chordoma, chondrosarcoma, meningioma), ocular melanoma when brachytherapy is not possible, selected paraspinal/sacral tumors, medulloblastoma/CSI in children, selected pediatric CNS tumors and axial skeletal/near-spine tumors, and selected adenoid cystic carcinomas of salivary/lacrimal glands.

    Supported by MSAC, Cancer Care Alberta, NHS and other assessments.

    Indications with insufficient evidence: For many common adult cancers (breast, prostate, lung, head and neck broadly, gastrointestinal and pelvic cancers) evidence is low or insufficient to conclude superiority of proton therapy over photon radiotherapy; routine commissioning not supported without prospective comparative data.

    Noted by multiple HTAs and guideline bodies as low-quality or insufficient evidence.

    Use in clinical trials/registries: Where evidence is limited, referral for proton therapy is recommended within prospective clinical trials or multi-institutional registries to generate comparative effectiveness and long-term toxicity data.

    Multiple systematic reviews and assessments emphasize the need for RCTs and registries.

    Pediatric considerations: Children may particularly benefit from proton therapy due to reduced dose to developing tissues and potentially lower lifetime risk of radiation-induced second malignancies; pediatric indications (e.g., medulloblastoma, certain CNS and axial tumors) are commonly listed as appropriate.

    Cited across assessments for dosimetric and long-term-risk rationale.

    Evidence-based considerations (informational)

    Evidence- and guideline-derived considerations relevant to coverage determinations

    General considerations: Proton therapy may be considered when photon-based therapy cannot meet normal tissue constraints or when dosimetric advantage is expected to reduce dose to critical structures; however, many indications lack high-quality comparative evidence.

    NCCN and other guidance note consideration when photon constraints cannot be met; HTAs emphasize limited comparative evidence.

    Re-irradiation for head and neck cancer: Retrospective multi-institutional series report tumor control with acceptable acute and late toxicity for proton re-irradiation, but follow-up is limited and selection criteria (prior RT history, interval since prior RT, performance status) are important.

    Based on Romesser et al., McDonald et al. series.

    Pediatric CNS/spine indications: Small series report favorable local control and low acute high-grade toxicity in pediatric spinal ependymoma and low-grade gliomas after PBT; long-term follow-up needed to assess late effects.

    Reports by Amsbaugh et al. and Greenberger et al.

    Ocular choroidal hemangioma: Retrospective series report tumor regression and visual stabilization with PBT, though comparative benefit over photons is not consistently demonstrated.

    Several small series summarized in policy.

    Dosimetric advantage evidence: Planning studies (e.g., seminoma, cervical cancer/IMPT) demonstrate reduced dose to organs at risk and modeled reductions in second cancer risk with PBT, but clinical outcome superiority is not established.

    Includes Efstathiou et al., Clivio et al. planning studies.

    Evidence summaries by indication

    Summary findings and caveats from cited studies (evidence-based observations):

    Cervical cancer (IMPT): Small IMPT series (n=11) showed improved DVH parameters versus VMAT and potentially comparable target coverage to MRI-guided brachytherapy for patients unable to undergo brachytherapy; findings are preliminary and require validation.

    Small patient series; NCCN does not list PBT for uterine neoplasms.

    Mesothelioma: Feasibility studies with small cohorts indicate IMPT deliverability with lower mean doses to several OARs and acceptable acute toxicity; evidence insufficient to demonstrate superiority over other modalities.

    Limited sample sizes and adjunct therapies confound interpretation.

    Pancreatic cancer (SBPT): Retrospective series (n=49) after induction chemotherapy reported 2-year OS 67.6%, LC 73.0% and grade ≥3 GI toxicity 6.1%; authors caution limitations due to retrospective design and limited follow-up.

    NCCN pancreatic guideline does not mention PBT.

    Rectal cancer: A systematic review/meta-analysis (8 articles; 127 patients) showed PBT reduced irradiated small bowel, bladder, and pelvic bone marrow versus photon RT; clinical outcome data remain limited.

    NCCN rectal cancer guideline does not list PBT.

    Retroperitoneal/pelvic sarcoma: Retrospective comparisons indicate peri-operative advanced-modality RT (including PBRT or IMRT) improved local recurrence-free survival versus surgery alone but did not significantly change disease-specific survival; peri-operative morbidity was higher in RT groups and randomized data are needed.

    Small cohorts; further randomized investigation recommended.

    Choroidal melanoma: Large retrospective series (n=351) reported many patients retain useful vision after PBRT even with foveal involvement; retrospective design limits causal inference.

    Dose variations studied; further study needed.

    Thymic tumors: Prospective cohort and small institutional series reported excellent local control and low early toxicity with proton therapy and dosimetric advantages versus IMRT; longer follow-up and prospective trials are needed.

    NCCN states PBT may be considered in certain circumstances for thymic tumors.

    Intracranial germ cell tumors: Dosimetric comparisons demonstrate superior target coverage and greater sparing of normal brain structures with proton techniques; clinical benefit requires validation.

    Pediatric CNS dosimetric rationale cited.

    Atypical meningioma: Small retrospective series report variable local control with particle RT; no definitive evidence of superiority to photon RT.

    Additional prospective data required.

    Sacral chordoma: Case reports and small series describe use of particle therapy (proton/carbon) often achieving favorable local control; trials and larger series with longer follow-up are needed.

    Limited sample sizes and retrospective designs.

    Recommended evaluation indications

    Situations discussed where particle therapy is recommended or should be evaluated

    Indications where protons should be evaluated: Chordoma or chondrosarcoma of the skull base; pediatric CNS tumors; cases requiring dose escalation for radio-resistant histologies or where critical-structure sparing is essential. (Protons should be considered where available but should not cause delays in care.)

    Policy and reviews recommend evaluation of protons for these scenarios while avoiding treatment delay.

    Evidence context

    Evidence summaries supporting use

    Evidence notes: Retrospective and single-arm studies report favorable local control and acceptable toxicity for sacral chordoma and skull-base bone sarcomas with particle therapy; Heidelberg reports high PFS at 36 and 60 months with low high-grade toxicity, but studies are non-randomized with limited sample sizes and follow-up.

    Findings require validation in prospective comparative trials.

    Pediatric CNS tumors

    Pediatric CNS considerations

    Pediatric specifics: Proton therapy may reduce integral dose and some late endocrine and cognitive toxicities in children; medulloblastoma cohorts report acceptable toxicity and similar survival to photons but notable rates of hearing loss and endocrine deficits persist; long-term comparative data are limited.

    Benefit is inferred from dosimetry and cohort analyses; randomized long-term data lacking.

    Reported clinical indications and outcome summaries

    Reported clinical contexts with reported outcomes (not formal coverage criteria):

    Skull-base/benign meningioma (SBM): Particle radiotherapy series report excellent local control and low toxicity for SBM (e.g., 100% PFS at 36 months, 96.6% at 60 months in a reported cohort), but prospective longer-term follow-up is needed.

    Single-institution and registry data summarized.

    Liver tumors (HCC/ICC): Phase II and prospective PBRT studies report high 2-year local control (~94%) and acceptable toxicity in selected unresectable HCC/ICC patients meeting trial criteria (e.g., Child-Pugh A/B, limited lesions).

    Evidence from multi-institutional single-arm trials and feasibility studies.

    Mediastinal lymphoma / Hodgkin lymphoma: Registry/observational series of consolidative proton therapy report excellent early 3-year relapse-free survival (~92%) and low early grade ≥3 toxicities; long-term comparative benefits versus modern photon RT remain unproven.

    Hoppe et al. registry data summarized.

    Background evidence summaries (informational)

    Evidence-summary statements relevant to coverage determinations

    Mediastinal lymphoma evidence: Proton therapy reduces normal tissue dose via the Bragg peak, but clinical evidence of outcome superiority in lymphoma is limited; patient selection and multidisciplinary discussion are essential, and careful management of organ motion and planning uncertainties is required.

    Editorials and registry data emphasize dosimetric advantage but limited clinical confirmation.

    Esophageal cancer evidence: A randomized phase IIB trial showed proton therapy reduced total toxicity burden versus IMRT while maintaining similar progression-free and overall survival; limitations include single-institution design and early closure, indicating need for multicenter confirmation.

    Lin et al. randomized trial findings summarized.

    Prostate cancer evidence: Available evidence indicates similar outcomes between PBT and IMRT for localized prostate cancer; randomized trials are ongoing and comparative effectiveness is currently insufficient to demonstrate superiority.

    Guideline and HTA statements characterize proton therapy for prostate as promising but not proven.

    High-grade meningioma evidence: Retrospective series suggest variable local control with particle therapy and low severe toxicity rates in selected cohorts, but randomized prospective trials are lacking.

    Systematic reviews report heterogeneous outcomes and limited quality.

    Retroperitoneal sarcoma evidence: Small series combining PBRT/IMRT with surgery (and IOERT in some reports) indicate low local recurrence for primary disease but data are limited and not definitive for survival benefit.

    Further randomized study recommended.

    Evidence-based coverage groupings

    Coverage stance and evidence highlights from the document:

    Neutron therapy — salivary gland tumors: Randomized and nonrandomized evidence demonstrate improved local/regional control with fast neutron radiotherapy for unresectable or recurrent malignant salivary gland tumors; although long-term morbidity is higher, life-threatening complications were not significantly different, and neutron therapy may be recommended for unresectable or gross residual disease.

    Based on randomized trial (Laramore et al.) and subsequent series.

    Proton/particle therapy — high-grade meningioma and selected sarcomas: Retrospective series (e.g., multiple small studies for high-grade meningioma and skull-base/spine sarcomas) report variable local control (range reported) and generally low severe toxicity in selected cohorts; data are retrospective and controlled trials are lacking.

    Evidence considered limited but supportive in selected indications.

    Carbon ion radiotherapy: Systematic assessments identified multiple studies but found no conclusive evidence of superiority or inferiority of CIRT versus standard irradiation across most indications; CIRT should be considered experimental/unproven at present.

    Ludwig Boltzmann and other systematic reviews concluded insufficient evidence for superiority.

    Other cancer sites and evidence limitations: For prostate, many sarcomas, lung, rectal, breast and other tumors the data are mixed with limited high-quality evidence; some small trials show improvements in toxicity or local control but overall evidence is heterogeneous and uncertain.

    HTAs and guideline bodies emphasize limited generalizability and need for RCTs.

    Coverage rationale and evidence-based conclusions

    Evidence summary and resulting policy stance

    General evidence conclusion: For the reviewed oncologic indications, current evidence does not permit firm conclusions of superiority or inferiority of carbon ion radiotherapy (CIRT) versus standard irradiation for most indications; therefore, CIRT is considered experimental for these indications.

    Systematic reviews identified limited comparative data and geographic concentration of studies.

    Bone sarcomas evidence: A systematic review/meta-analysis of CIRT for bone sarcomas reported promising local control and overall survival rates with mainly grade 1–3 toxicities, suggesting CIRT is promising for unresectable or residual bone sarcomas but randomized trials are needed to establish superiority versus other modalities.

    Meta-analysis included 12 studies and 897 patients; limitations include case-series designs and regional concentration of reports.

    The policy lists example adult ICD‑10 diagnoses for which proton beam radiotherapy (PBRT) is identified as not-covered (examples, not all‑inclusive). These include malignancies of the small intestine (C17.0–C17.9), rectum/rectosigmoid/anus (C19–C21.8), liver and intrahepatic bile ducts (C22.2–C22.9), pancreas (C25.0–C25.9), lung including non‑small‑cell lung carcinoma (C34.00–C34.92), ethmoidal sinus (C31.1), malignant melanoma of skin (C43.0–C43.9), mesothelioma (C45.0–C45.9), and a range of soft tissue and other adult tumor codes listed in the ICD‑10 tables in the policy.

    Multiple health‑technology assessments and reviews conclude it is not appropriate to routinely propose proton therapy for certain indications because of inadequate or low‑quality evidence. Assessments specifically note proton therapy is presently not recommended or considered premature for indications including non‑small‑cell lung cancer and some thoracic cancers, hepatocellular carcinoma, prostate cancer, esophageal cancer, breast cancer, and routine re‑irradiation outside prospective studies or registries.

    Available assessments and guideline statements do not support routine primary use of proton beam therapy for localized prostate cancer outside clinical trials or registries. Comparative evidence indicates outcomes with PBRT and IMRT are similar, randomized data have not demonstrated superiority, and technology assessments have judged the comparative effectiveness and value as insufficient to justify routine proton use for prostate cancer absent plan‑specific coverage provisions.

    Multiple guideline sections and technology assessments do not recommend routine proton therapy for several malignancies, including Hodgkin lymphoma and cholangiocarcinoma. For lymphoma, guideline panels and technology reviews report insufficient clinical outcome data to demonstrate PBT superiority and do not make broad recommendations for routine use. International and national reviews likewise do not endorse routine PBT for cholangiocarcinoma, and NCCN guidance does not list PBT as a standard option for several of these sites.

    For multiple tumor types — for example uterine neoplasms, pancreatic adenocarcinoma, and rectal cancer — cited NCCN guidance and systematic reviews do not list proton beam therapy as a standard therapeutic option. The document summarizes small feasibility and retrospective series for some of these sites but concludes that clinical outcome evidence is limited and that NCCN does not include PBT as a recommended standard treatment for these indications.

    The policy states that the use of protons is not justified if it would cause a delay or lead to inferior oncologic care compared with available photon‑based treatments. Treatment decisions should avoid unacceptable delays (for example delaying adjuvant radiotherapy) or selection of PBT when equivalent photon techniques can deliver appropriate oncologic therapy without compromise.

    For CNS malignancies other than skull‑base and cervical spine chordomas and chondrosarcomas, ASTRO and several assessments indicate the potential benefit of proton beam therapy remains theoretical and requires further study. While protons are commonly evaluated for selected skull‑base lesions, evidence for broader CNS indications is limited and international guidelines generally make no broad recommendation for routine PBT use outside select skull‑base or pediatric indications.

    NCCN guidance does not preferentially recommend proton therapy over photons for B‑cell lymphomas and advises that for esophageal cancer proton therapy data are early and evolving; NCCN states that PBT for esophageal cancer should ideally be delivered in the context of a clinical trial. Overall, NCCN does not list PBT as the default modality for most lymphoma or esophageal scenarios.

    Carbon ion radiotherapy (CIRT) is considered experimental or unproven for the oncologic indications assessed in the policy. Systematic assessments identified multiple studies but concluded that for the majority of evaluated indications there is insufficient evidence to establish superiority or equivalence versus standard irradiation; therefore CIRT is excluded from routine coverage absent strong investigational justification or case‑level review.

    Across assessed oncologic indications, carbon ion radiotherapy lacks sufficient high‑quality evidence to conclude superiority or inferiority compared with standard photon or proton irradiation. The systematic reviews and meta‑analyses summarized in the policy report promising outcomes in some series (for example unresectable bone sarcomas) but emphasize geographic concentration of studies, heterogeneity, and lack of randomized comparative data; thus CIRT remains experimental for the listed indications.

    The document’s references section includes citations specific to Neutron Beam Therapy, but this references listing does not itself state coverage exclusions; substantive policy statements about neutron therapy indications and evidence appear elsewhere in the policy text and summaries.

    This Clinical Policy Bulletin provides a general summary of plan benefits and evidence considerations and is not a contract nor a substitute for the member’s benefit plan documents. Providers and members should refer to the member’s plan provisions for definitive coverage and contractual terms.

    The policy explicitly states that proton beam radiotherapy is considered experimental and investigational for all indications not specified as medically necessary in the bulletin; example adult lists are provided in the policy text to illustrate conditions for which PBRT would not be considered medically necessary.

    The Washington State Health Technology Clinical Committee determined that proton beam therapy is covered for specified primary cancers in adults (e.g., esophageal, head/neck, skull‑based, hepatocellular carcinoma, brain/spinal, ocular) subject to conditions, and that PBT is not covered for other adult conditions beyond those specified, reflecting regional coverage restrictions noted in the assessments.

    For non‑small‑cell lung cancer and several other indications, technology assessments and guideline reviews conclude evidence is insufficient to support routine PBT use; comparative effectiveness versus established photon options (including SBRT for early‑stage NSCLC) is uncertain and PBT does not meet routine‑use criteria outside trials or registries.

    Where guidelines or health‑technology assessments explicitly state evidence is insufficient (for example ASTRO reviews, AHRQ assessments, and other HTAs), the policy summarizes that proton beam therapy would generally be considered not medically necessary relative to established photon therapies unless specific, justifying clinical circumstances exist or the patient is enrolled in a prospective trial/registry.

    Many feasibility and dosimetric optimization studies cited in the policy are small and primarily report planning or technical outcomes rather than clinical effectiveness. The policy highlights that where only feasibility or dosimetric data exist without comparative clinical outcome evidence, PBRT should be considered unproven for those indications pending higher‑quality clinical data.

    The policy cautions against using protons solely when advanced photon techniques (e.g., IMRT/VMAT, brachytherapy) can provide equivalent oncologic care, particularly if proton access would delay treatment or compromise outcomes. Where photon constraints can be met, photon‑first approaches are recommended and proton selection should be justified by inability of photon techniques to meet normal‑tissue constraints.

    Comparative evidence for many CNS indications is limited and of poor quality; the policy notes absence of demonstrated superiority of PBT for broad CNS tumor groups and cites some adjusted analyses suggesting worse outcomes in particular series, underscoring the need for caution and additional justification when proposing PBT for non‑skull‑base CNS tumors.

    For localized prostate cancer, the policy reflects that evidence is insufficient to show a clinical benefit of proton therapy over established options such as IMRT. Randomized data have not demonstrated superiority, and comparative clinical‑effectiveness assessments rate the evidence as inadequate to support routine proton use for most prostate indications.

    CIRT is deemed to lack sufficient evidence of superiority or well‑established indications and therefore is considered experimental. The policy states that carbon‑ion therapy should be excluded from routine coverage and that investigational justification or case‑level review would be required for its consideration.

    Systematic assessments summarized in the policy found that for many oncologic indications (54 assessed sites) neither superiority nor inferiority of CIRT versus standard irradiation can be concluded from current evidence; accordingly, carbon ion radiotherapy must currently be treated as experimental and not medically necessary for routine coverage.

    The policy includes an extensive references list for carbon ion radiotherapy; these citations are provided for context and do not themselves change the policy’s conclusion that CIRT is experimental and not established for routine coverage.

    Billing Codes and Diagnostic Mapping

    Covered CPT/HCPCS codes for PBRT (if selection criteria met)CPTCovered
    77520Proton treatment delivery; simple, without compensation.
    77522Proton treatment delivery; simple, with compensation.
    77523Proton treatment delivery; intermediate.
    77525Proton treatment delivery; complex.
    61796Stereotactic radiosurgery (particle beam, gamma ray or linear accelerator); 1 simple cranial lesion.
    61797Each additional cranial lesion, simple.
    617981 complex cranial lesion.
    61799Each additional cranial lesion, complex.
    63620Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion.
    63621Each additional spinal lesion, complex.
    1–10 of 13
    1/2
    Covered CPT codes for neutron beam therapy (if selection criteria met)CPTCovered
    77423High energy neutron radiation treatment delivery, 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s).
    61796Stereotactic radiosurgery (particle beam, gamma ray or linear accelerator); 1 simple cranial lesion.
    CPT codes not covered for Carbon Ion Radiotherapy (CIRT)CPTNot Covered
    No codes listed
    Example ICD-10 codes covered for PBRT when selection criteria are met (adult and pediatric lists present)ICD-10Covered
    C00.0-C00.9Malignant neoplasm of lip
    C11.0-C11.9Malignant neoplasm of nasopharynx
    C22.0Liver cell carcinoma
    C69.30-C69.32Malignant neoplasm of choroid
    C71.0-C71.9Malignant neoplasm of brain
    C48.0Malignant neoplasm of retroperitoneum (retroperitoneal sarcoma)
    Q85.01Neurofibromatosis, type 1
    Z15.01Genetic susceptibility to malignant neoplasm of breast
    Z94.0Kidney transplant status
    ICD-10 codes listed as not covered for PBRT (examples, not all-inclusive)ICD-10Not Covered
    C34.00-C34.92Malignant neoplasm of bronchus and lung [including non-small-cell lung carcinoma]
    C50.01-C50.929Malignant neoplasm of breast
    C61Malignant neoplasm of prostate
    C25.0-C25.9Malignant neoplasm of pancreas
    C43.0-C43.9Malignant melanoma of skin
    Coding references in excerptmixed
    none listedNo CPT/HCPCS/ICD codes are specified in this excerpt.
    Pediatric age threshold — PBRT
    Pediatric age thresholdMalignancies in children 21 years of age and younger are listed as medically necessary indications for PBRT
    Age cutoff value≤ 21 years of age
    Context of applicationApplies when treating pediatric malignancies with curative intent (included among PBRT medical necessity indications)

    Prior Authorization, Documentation, and Decision Support

    Prior Authorization

    Prior Authorization — Verify Plan-Specific Requirements

    Prior authorization requirements for particle-beam therapies vary by indication, plan, and complexity of the proposed treatment. Providers should verify prior authorization requirements with the member's benefit plan before scheduling PBRT, NBT, or CIRT. When prior authorization is required, documentation should demonstrate that indication-specific and plan-level medical necessity criteria are met.

    • Verify plan-specific prior authorization requirements and medical necessity definitions before submission.
    • When prior authorization is requested, include indication-specific documentation (tumor type, stage, prior therapies, intent of treatment).
    • For ICD-10 diagnoses listed as not covered in this policy for adults, expect denial risk if PBRT is requested for those indications.
    Prior Authorization

    Indication-Based Prior Authorization

    Indication-based prior authorization is recommended. Coverage determinations commonly reference indication groupings (e.g., ASTRO Group 1 vs Group 2). Prior authorization submissions should identify the indication, cite relevant guideline grouping (if applicable), and provide supporting clinical evidence.

    • Document whether the indication aligns with Group 1 (frequently supported) or Group 2 (coverage with evidence development) per ASTRO model policies where applicable.
    • For Group 2 indications, include rationale for coverage with evidence development or trial/registry enrollment plans.
    Prior Authorization

    Prior Authorization for Limited / Selected Indications

    Prior authorization is recommended for selected or limited indications where guidelines and health-technology assessments recommend PBRT only for specific diagnoses or after multidisciplinary review. Submissions should include multidisciplinary tumor board review notes when applicable.

    • Include tumor board documentation when PBRT is proposed for adult indications that some assessments consider conditional or restricted.
    • For adult indications noted as covered with conditions by regional assessments (e.g., Washington State), include documentation that conditions are met.
    Prior Authorization

    Prior Authorization Recommended for PBT

    Prior authorization is recommended when proton-beam therapy (PBT) is proposed, particularly for indications lacking clear guideline endorsement or high-quality comparative evidence.

    • For adult indications deemed experimental/investigational in this policy, anticipate case-level review and potential denial.
    • For pediatric and other supported indications, prior authorization supports timely coordination of care and documentation of intent.
    Prior Authorization

    Prior Authorization Recommended for Complex PBRT Cases

    Complex PBRT cases (e.g., multiple isocenters, many energy layers, combined modality treatment, reirradiation) should undergo prior authorization with submission of detailed treatment planning and intent documentation.

    • Provide a summary of the proposed treatment plan, number of isocenters, beam arrangement, and expected energy layers.
    • Include robustness analysis, image-guided setup plans, and how organ motion will be managed.
    • Document treatment intent (curative vs palliative), prior radiation history, and timing since prior RT if reirradiation is proposed.
    Prior Authorization

    Prior Authorization — Avoid Treatment Delay

    Prior authorization processes must avoid causing unacceptable delays in oncologic care. Submissions should include timing constraints to ensure adjuvant or time-sensitive radiotherapy starts within clinically acceptable windows.

    • Document planned radiotherapy start date and any postoperative timing limits (e.g., adjuvant RT initiation goals).
    • Prior authorization reviews should be expedited for cases where delay could harm outcomes.
    Prior Authorization

    Prior Authorization / Registry Enrollment Recommended

    When proton therapy is used as consolidative therapy (e.g., Hodgkin lymphoma) or for indications with limited evidence, prior authorization or registry/IRB-approved protocol enrollment is recommended to support evidence development and tracking of outcomes.

    • Include registry or IRB protocol identifiers when available.
    • If not enrolled in a trial, provide rationale for use outside of research and evidence of multidisciplinary review.
    Prior Authorization

    Consideration for Trial Enrollment

    When data are limited or evolving, consider enrollment of patients in prospective clinical trials. Guidelines (e.g., NCCN for esophageal cancer) recommend ideally treating with PBT within a clinical trial when feasible.

    • Document trial eligibility or reasons trial enrollment was not possible.
    • Provide trial or registry identifiers and informed consent documentation when applicable.
    Prior Authorization

    Carbon Ion Therapy Experimental — Case Review Suggested

    Carbon ion radiotherapy (CIRT) is considered experimental/unproven for the indications assessed. Case-level review and institutional IRB/trial enrollment are suggested prior to authorization for CIRT.

    • CIRT should be documented as investigational in the submission; include protocol and justification.
    • Expect case-by-case review and likely denial outside of approved clinical trials or registries.
    Note

    Prior Authorization Not Addressed in This Segment

    Some parts of this policy and its reference listings do not specify prior authorization rules. Where the policy or references are silent, revert to the member's benefit plan provisions and Clinical Policy Bulletin for authorization processes.

    • No specific prior authorization requirements are contained in certain reference sections; check plan documents.
    • If prior authorization is not addressed in the policy excerpt, use standard plan submission pathways.
    Note

    Prior Authorization Not Specified in These Chunks

    Some reference chunks and coding lists do not specify prior authorization or denial requirements. Providers should not assume coverage based solely on code listings; verify clinical criteria and plan rules.

    • Coding lists alone do not guarantee coverage; clinical criteria and plan provisions drive authorization decisions.
    • Contact the payer for any code- or indication-specific prior authorization instructions.
    Denial Risk

    Denial Risk for Non-Covered ICD-10 Indications

    Denial risk is elevated when PBRT is requested for ICD-10 diagnoses specifically listed as not covered for adults in this policy. Providers should confirm the ICD-10 code maps to a covered indication and include supporting documentation.

    • Review the policy's 'ICD-10 codes not covered' lists before submission.
    • If the diagnosis is on the not-covered list, include compelling justification and tumor-board documentation if requesting exception review.
    Denial Risk

    Coverage Restrictions for Adults per Washington State Assessment

    Regional technology assessments (e.g., Washington State) place coverage restrictions for adults for many indications. Prior authorization submissions should reference such assessments and demonstrate compliance with their conditions when relevant.

    • For adults, include documentation that meets regional assessment conditions (e.g., specific cancer types, multidisciplinary review) when applicable.
    • If the regional assessment does not support coverage for the indication, be prepared for denial.
    Denial Risk

    Unproven Comparative Effectiveness May Lead to Denial

    In the absence of high-quality randomized comparative evidence or guideline endorsement, PBRT requests for many indications may be denied or require enrollment in evidence-development programs.

    • Include the best available comparative evidence and rationale for expected benefit over alternative therapies.
    • If comparative effectiveness is unproven, document why alternatives are unsuitable or would exceed normal tissue constraints.
    Denial Risk

    Evidence Insufficiency May Prompt Denial

    Insufficient evidence for an indication is a common reason for denial. Providers should supply prospective trial data, registry enrollment, or robust rationale when evidence is limited.

    • When evidence is insufficient, document the clinical need, prior treatments tried, and why standard options are unsuitable.
    • Consider suggesting treatment within a clinical trial or registry if available.
    Denial Risk

    Guideline Non-Endorsement May Affect Coverage

    Lack of guideline endorsement for an indication (e.g., NCCN, ASTRO) may affect coverage decisions. Prior authorization should reference current guideline positions and explain deviation when proposing PBRT.

    • Cite specific guideline statements and provide clinical justification when requesting PBRT outside guideline-listed options.
    • If guidelines recommend photon-first approaches, document attempts or infeasibility of photon-based therapy.
    Prior Authorization

    Timeliness of Therapy — Expedite When Clinically Needed

    Timeliness of therapy is critical. Prior authorization processes must not create delays that compromise oncologic outcomes (for example, undue delay of adjuvant radiotherapy). Document time-sensitive treatment milestones in the authorization request.

    • Provide planned treatment initiation dates and clinical rationale for timing.
    • Requests for expedited review should state the clinical consequences of delay.
    Documentation Required

    Technical Planning / Setup Risks — Document Mitigation

    Technical planning and setup risks (e.g., sensitivity to tissue density, organ motion, end-of-range uncertainty) should be addressed in submissions. Include treatment-planning reports, robustness analyses, and daily image-guidance strategies.

    • Attach planning CT/MRI summaries, motion-management strategies, and verification QA documentation.
    • For mediastinal and thoracic plans, document respiratory gating, margins, and verification steps to mitigate dose uncertainty.
    Denial Risk

    Higher Risk of Damage to Surrounding Tissues — Justify Use

    Certain technologies (e.g., neutron beams) carry higher risks to surrounding tissues due to greater energy deposition; when used, prior authorization should include detailed risk-benefit analysis and justification.

    • Explain why neutron beam therapy is preferred for the specific tumor type and why alternatives are unsuitable.
    • Provide toxicity mitigation strategies and expected benefit over standard approaches.
    Note

    Plan-Level Medical Necessity Considerations

    Benefit-plan medical necessity considerations may include comparative costs of alternative treatments. Prior authorization should reference plan definitions of medical necessity where cost-comparative considerations apply.

    • Check member benefit plan language for medical necessity definitions and comparative cost considerations.
    • Include discussion of why alternative, lower-cost options are not appropriate when relevant.
    Note

    This Section Contains Only Literature References — Check Plan Rules

    This portion of the policy includes literature references; some sections contain only references and do not specify authorization, denial, or documentation requirements. Providers should not infer coverage from referenced studies alone.

    • When the policy section is reference-only, follow the Clinical Policy Bulletin and plan provisions for submission requirements.
    • Provide clinical documentation as required by the plan even if literature supports the intervention.
    Documentation Required

    Documentation Requirements for Authorization and Case Review

    Documentation expectations for prior authorization and case review: provide comprehensive, indication-specific clinical records and treatment-planning information to support medical necessity determinations.

    • Documentation of indication-specific criteria: tumor histology, stage, size, resection status, and rationale for PBRT versus alternatives.
    • Indication categorization: state whether the case aligns with ASTRO Group 1 or Group 2 and provide supporting evidence.
    • Supportive clinical trial documentation: include protocol details, eligibility, dosing, and follow-up plans when applicable.
    • Suggested documentation elements: prior radiation history, time since prior RT, performance status (e.g., Karnofsky), imaging, and pathology reports.
    • Treatment planning and QA documentation: dose distributions, DVHs, robustness analysis, image-guided setup, and daily verification plans.
    • Required clinical documentation: tumor histology/grade, proximity to critical structures, prior therapies, intent of treatment (curative vs palliative).
    • Trial eligibility-like documentation: when using trial criteria, include Child-Pugh status, lesion number/size limits, and performance status where relevant.
    • Planning and justification notes: explain management of internal organ motion, immobilization, and plan robustness for mediastinal and thoracic cases.
    Step Therapy

    Evidence-Driven Sequencing — Photon-First When Feasible

    Evidence-driven sequencing and conservative use of PBRT are expected. Where normal tissue constraints can be met with photon-based therapy, photon-first approaches (IMRT/VMAT/SRS) should be considered and documented before PBRT is pursued in many adult settings.

    • When photon therapy can meet constraints, document why PBRT is preferred or why photon approaches are not feasible.
    • Document prior use or consideration of standard therapies when policy or guidelines recommend photon-first approaches.
    Documentation Required

    Comparative Approach Requirement — Document Alternatives Considered

    Comparative approach requirement: document consideration of advanced photon techniques (IMRT/VMAT/SRS) and why particle therapy is expected to provide clinically meaningful advantage for the individual patient.

    • Provide comparative dosimetry summaries and expected normal tissue sparing with PBRT versus advanced photon plans.
    • If proton therapy follows surgery (pre- or post-operative) or is combined with other modalities, document the multidisciplinary treatment plan.
    Step Therapy

    Stepwise Use After Standard Therapies

    Stepwise use after standard therapies: For select indications (e.g., conjunctival SCC/OSSN), standard first-line therapies (surgery, topical agents) are expected before considering PBRT; document prior treatments and indications for PBRT.

    • For indications where standard therapies exist, include records of prior attempts and reasons for failure or ineligibility.
    • When PBRT is used as salvage or for refractory disease, attach prior-treatment summaries and timelines.
    Documentation Required

    Prostate Therapy Sequencing and Evidence Considerations

    Prostate therapy sequencing: randomized trials comparing proton therapy to IMRT are ongoing; until high-quality evidence is available, proton therapy for localized prostate cancer is considered clinically equivalent to IMRT and medical necessity is determined by the member's benefit plan.

    • Check benefit plan descriptions for coverage position on prostate PBRT.
    • If requesting PBRT post-prostatectomy or in the postoperative setting, include comparative rationale and expected benefits.
    Documentation Required

    Use of Proton-Beam Therapy Often Described in Combination With Other Modalities

    Use of proton-beam therapy is often described in combination with surgery, IMRT, and intra-operative electron radiotherapy (IOERT). Multidisciplinary coordination and documentation of combined-modality intent are expected in authorization submissions.

    • Include surgical reports, planned sequence of therapies, and rationale for combining modalities.
    • Document expected contribution of PBRT to the overall treatment strategy and goals (local control, organ preservation, reduced toxicity).
    Note

    Provider Action — Refer to Clinical Policy Bulletin and Plan Provisions

    Providers should refer to the Clinical Policy Bulletin and the member's plan provisions for the definitive guidance on prior authorization processes, documentation formats, and coverage determinations.

    • Clinical Policy Bulletins assist in administering plan benefits but do not replace plan-specific benefit language.
    • When in doubt, contact the payer's medical policy/prior authorization help line for submission instructions and required forms.

    Background and Scope

    Background: Proton beam radiotherapy (PBRT) is an external‑beam charged‑particle modality that delivers dose with a distinct depth‑dose distribution (Bragg peak) enabling reduced exit dose and potential sparing of adjacent normal tissues. PBRT is most commonly considered for tumors adjacent to critical structures, many pediatric malignancies, selected skull‑base or ocular tumors, and some re‑irradiation scenarios where photon techniques cannot meet normal‑tissue constraints.

    Definitions and Key Terms

    Proton beam radiotherapy (PBRT)
    DefinitionA type of external beam radiation therapy using protons to deliver targeted radiation with less scatter to surrounding tissues.
    Clinical rationaleProtons can penetrate to deep tumors while delivering less dose to superficial tissues, potentially sparing adjacent normal structures.
    Common usesUsed for tumors near critical structures (e.g., uveal melanoma, skull-base chordomas/chondrosarcomas) and when minimizing dose to healthy tissue is important.
    Carbon ion radiotherapy (CIRT)
    DefinitionParticle beam therapy using carbon ions
    Policy stanceConsidered experimental and investigational for all indications per this policy; effectiveness not established.
    Evidence summarySystematic assessments found insufficient evidence of superiority or inferiority of CIRT for multiple oncologic indications.
    Proton Beam Therapy (PBT)
    DefinitionA form of charged-particle radiotherapy using protons intended to deliver dose with distinct depth-dose characteristics compared with photon radiotherapy (Bragg peak properties).
    Dose characteristicDelivers maximum energy near end of range (Bragg peak), allowing reduced exit dose to normal tissues compared with photons.
    Clinical implicationUsed to spare adjacent critical structures and enable dose escalation in select tumors when appropriate.
    Coverage with Evidence Development (CED)
    DefinitionCoverage with Evidence Development (CED) — coverage contingent on participation in prospective studies or registries to generate higher-quality comparative data.
    Use caseApplied to indications categorized by professional societies (e.g., ASTRO Group 2) where evidence is limited and further data are needed.
    Documentation implicationEnrollment in trials/registries and trial-like documentation is expected when CED is the coverage pathway.
    RTOG/EORTC morbidity scoring
    DefinitionRTOG/EORTC morbidity scoring — standardized grading system used to report acute and late morbidity/outcomes in radiation therapy studies.
    PurposeUsed in clinical reports cited in the policy to grade adverse events and compare toxicity across series.
    ApplicationReferenced when summarizing toxicity outcomes in pediatric and head & neck re-irradiation series within the document.
    Cobalt Gray Equivalent (Gy(E))
    DefinitionCobalt Gray Equivalent (Gy(E)) — a unit used to express biological dose for proton beam radiotherapy regimens in cited clinical trials.
    ContextReported in prospective PBRT HCC trials (e.g., Kawashima: 76 Gy(E) in 20 fractions).
    InterpretationUsed to compare proton dose regimens in clinical reports within the policy document.
    CGE (Cobalt Gray Equivalent)
    DefinitionCGE (Cobalt Gray Equivalent) = proton Gy × relative biological effectiveness (RBE); document uses RBE ≈ 1.1.
    Clinical useApplied to convert physical proton dose to biologically weighted dose reported in trials and series.
    ExampleUsed in reporting PBRT regimens and outcomes in HCC and other cited studies within the policy.
    IMPT — Intensity-modulated proton therapy
    DefinitionIMPT — Intensity-modulated proton therapy; a spot-scanning/energy-layer technique that modulates proton intensity to shape conformal dose distributions similar to IMRT.
    Technical noteDelivery time depends on number of energy layers; optimization can reduce energy layers without degrading dosimetry (feasibility studies cited).
    Clinical roleUsed as a potential boost alternative (e.g., cervical cancer patients unable to undergo brachytherapy) and to spare organs at risk in select cases.
    IMPT — Intensity modulated proton therapy (spot-scanning)
    DefinitionIMPT — spot‑scanning proton delivery using variable energies to cover target depth; intensity modulation shapes dose distribution.
    Planning implicationIMPT plans may provide superior DVH parameters and organ-at-risk sparing compared with VMAT/RA in small series; preliminary findings require validation.
    LimitationsSmall study sizes (e.g., n=11) limit generalizability; NCCN may not list PBT as option for some indications (e.g., uterine neoplasms).
    EQD2 — 2 Gy equivalent dose
    DefinitionEQD2 — 2 Gy equivalent dose (equivalent dose in 2‑Gy fractions) used to compare fractionation regimens (α/β specified in studies).
    Use in documentApplied in dosimetric comparisons (e.g., IMPT vs VMAT) to evaluate organ-at-risk doses and toxicity risk estimates.
    InterpretationFacilitates comparison across differing fractionation schedules reported in cited studies.
    Particle radiotherapy
    DefinitionParticle radiotherapy — radiation therapy using charged particles (protons, carbon ions) characterized by distinct dose deposition (Bragg peak) enabling reduction of exit dose to normal tissues.
    Modalities includedIncludes proton beam therapy and carbon ion radiotherapy; neutron and boron neutron capture therapies are distinct high-LET modalities described separately.
    Evidence noteComparative clinical advantages over photon therapy remain uncertain for many common cancers; systematic assessments call for randomized trials or registries.
    Cranio-spinal irradiation (CSI)
    DefinitionCranio-spinal irradiation (CSI) — irradiation of the entire craniospinal axis, commonly used in medulloblastoma treatment and deliverable with protons to potentially reduce dose to non-target tissues.
    Clinical evidencePediatric medulloblastoma series reported cranio-spinal doses in GyRBE with measurable rates of hearing loss and neuroendocrine deficits; long-term outcomes require follow-up.
    ApplicationCSI with protons is an indicated PBRT use when no active extracranial disease is present (per medical necessity list).
    Bragg peak
    DefinitionBragg peak — physical property of protons where energy is deposited near the end of their range allowing reduced exit dose to normal tissues.
    Clinical implicationEnables sparing of normal tissues beyond the target but creates sensitivity to tissue density changes and organ motion impacting dose accuracy.
    Planning considerationRequires careful plan robustness analysis and daily setup management to avoid dose uncertainty in critical normal tissues (noted for mediastinal RT).
    IMPT — intensity-modulated proton therapy
    DefinitionIMPT — intensity modulation applied to proton beams to shape dose distribution similar to IMRT for photons.
    BenefitCan improve target conformity and reduce dose to organs at risk in planning studies; clinical superiority over advanced photons not yet established for many indications.
    Operational noteSpot‑scanning IMPT delivery time depends on number of energy layers; optimization methods may reduce energies and improve throughput.
    Bragg peak (reiteration)
    DefinitionBragg peak — phenomenon where protons deposit most of their energy near the end of their range, producing minimal exit dose beyond the target.
    RelevanceUnderlying physical basis for proton dose-sparing of distal normal tissues and rationale for clinical use in tumors adjacent to critical structures.
    Planning cautionBragg-peak tail effects and radiobiological uncertainties require consideration during beam arrangement to avoid dose uncertainty in critical tissues.
    Total Toxicity Burden (TTB)
    DefinitionTotal Toxicity Burden (TTB) — a composite score of multiple adverse events and postoperative complications quantified over 1 year following treatment (used as primary endpoint in a randomized esophageal cancer trial).
    Trial relevanceUsed as the primary outcome in the NRG-GI006 trial comparing PBT versus IMRT for esophageal cancer; showed lower TTB with PBT while PFS/OS were similar.
    Interpretation cautionTTB has not been fully validated as a surrogate for long-term clinical outcomes; trial limitations noted include early closure and single‑institution design.
    Neutron beam therapy (NBT / NBRT)
    DefinitionNeutron beam therapy (NBT/NBRT) — external beam radiotherapy using high-energy neutrons produced from an accelerator; characterized by reduced oxygen enhancement factor and higher energy deposition compared with photons.
    Clinical useHistorically used mainly for salivary gland cancers and selected radioresistant tumors; planning and delivery are technically challenging and availability limited.
    Risk profileNeutrons deposit substantially more energy and may increase damage to surrounding tissues; long-term morbidity can be higher despite improved local control in some randomized trials for salivary gland tumors.
    Boron neutron capture therapy (BNCT)
    DefinitionBoron neutron capture therapy (BNCT) — a two-step therapy where tumor-selective boron uptake is followed by thermal neutron irradiation causing localized high-LET particle reactions that destroy boron-containing tumor cells.
    Distinct modalityDifferent from fast neutron therapy; involves tumor-targeted boron agents and subsequent neutron activation to induce localized cytotoxicity.
    Typical applicationOften investigated for brain tumors and other difficult-to-treat lesions where selective targeting is advantageous.
    Carbon ion radiotherapy (CIRT) — evidence summary
    DefinitionCarbon ion radiotherapy (CIRT) — high‑LET particle radiotherapy using accelerated carbon ions.
    Evidence conclusionSystematic reviews and health-technology assessments found insufficient evidence to conclude superiority or inferiority of CIRT versus standard irradiation for most indications; considered experimental for many oncologic sites.
    Clinical implicationCIRT should generally be considered investigational and would require case‑level justification or trial enrollment per this policy.

    Policy Dates and References

    1998-07-16Policy effective

    Policy became effective on 1998-07-16.

    2023-10-03Last reviewLatest

    Policy last reviewed on 2023-10-03.

    2024-03-14Next scheduled review

    Next scheduled policy review on 2024-03-14.